New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 12, 2013
06:30 EDTIMUCImmunoCellular downgraded to Neutral from Buy at Roth Capital
Roth Capital downgraded ImmunoCellular due to the failure of the Ph II ICT-107 study. Price target lowered to $2 from $9.
News For IMUC From The Last 14 Days
Check below for free stories on IMUC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 21, 2014
16:03 EDTIMUCImmunoCellular says ICT-107 Phase II data abstract accepted for presentation
Subscribe for More Information
April 15, 2014
08:19 EDTIMUCLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use